The efficacy of a human interleukin 12/23 monoclonal antibody and investigation of expression of IL12/23p40 in Crohn disease anorectal lesion.

The efficacy of a human interleukin 12/23 monoclonal antibody and investigation of expression of IL12/23p40 in Crohn disease anorectal lesion. - The efficacy of a human interleukin 12/23 monoclonal antibody and investigation of expression of IL12/23p40 in Crohn disease anorectal lesion.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000028761

Enrollment

100

Registered

2017-08-21

Start date

2017-08-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who introduce a human interleukin 12/23 monoclonal antibody in Crohn's disease anal lesion

Exclusion criteria

Exclusion criteria: Age under 10 yrs. Patients without consent.

Design outcomes

Primary

Measure	Time frame
the efficacy of a human interleukin 12/23 monoclonal antibody in Crohn's disease anorectal lesion	—

Secondary

Measure	Time frame
A Blood cytokine expression status before and after administration of a human interleukin 12/23 monoclonal antibody	—

Countries

Japan

Contacts

Public ContactHiroki Ikeuchi

Hyogo College of Medicine Department of Inflammatory Bowel Disease

Ikeuci2s@hyo-med.ac.jp0798456371

Outcome results